Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD’s Excedrin Review Gives Novartis A Headache

This article was originally published in The Tan Sheet

Executive Summary

Novartis will appeal a National Advertising Division recommendation that it discontinue or alter its claim that Extra Strength Excedrin will "start relieving your headache in just 15 minutes.

You may also be interested in...



National Advertising Division In Brief

Novartis to discontinue or modify Excedrin claim: Novartis agrees to discontinue or modify its claim that Extra Strength Excedrin will begin to relieve a headache in 15 minutes after the National Advertising Review Board upholds a previous National Advertising Division decision that the firm appealed, NARB says Nov. 24. The appeals division of the Council of Better Business Bureaus reviewed claim-substantiation materials that Novartis submitted to NAD after the firm's express claim for its headache product was challenged by Wyeth, which markets competing headache relief product Advil and has since been acquired by Pfizer (1"The Tan Sheet" March 23, 2009 and 2"The Tan Sheet" Oct. 26, 2009). In March, NAD decided that Novartis' substantiation did not support the claim that the product is the "only gel tab with a triple ingredient formula to start relieving your headache in just 15 minutes." NAD also considered an implied claim the product would provide considerable, if not total, relief in that time. NARB explained that it agrees with NAD's decision that "Novartis did not provide sufficient substantiation for the express claim that Extra Strength Excedrin starts to relieve headache pain in 15 minutes, and recommended that Novartis either discontinue or substantially modify that claim." According to NARB's report, Novartis said it "will, if it uses a similar claim in the future, take NAD's and NARB's conclusions into consideration in formulating and presenting the claim.

National Advertising Division In Brief

Novartis to discontinue or modify Excedrin claim: Novartis agrees to discontinue or modify its claim that Extra Strength Excedrin will begin to relieve a headache in 15 minutes after the National Advertising Review Board upholds a previous National Advertising Division decision that the firm appealed, NARB says Nov. 24. The appeals division of the Council of Better Business Bureaus reviewed claim-substantiation materials that Novartis submitted to NAD after the firm's express claim for its headache product was challenged by Wyeth, which markets competing headache relief product Advil and has since been acquired by Pfizer (1"The Tan Sheet" March 23, 2009 and 2"The Tan Sheet" Oct. 26, 2009). In March, NAD decided that Novartis' substantiation did not support the claim that the product is the "only gel tab with a triple ingredient formula to start relieving your headache in just 15 minutes." NAD also considered an implied claim the product would provide considerable, if not total, relief in that time. NARB explained that it agrees with NAD's decision that "Novartis did not provide sufficient substantiation for the express claim that Extra Strength Excedrin starts to relieve headache pain in 15 minutes, and recommended that Novartis either discontinue or substantially modify that claim." According to NARB's report, Novartis said it "will, if it uses a similar claim in the future, take NAD's and NARB's conclusions into consideration in formulating and presenting the claim.

National Advertising Division In Brief

Novartis to discontinue or modify Excedrin claim: Novartis agrees to discontinue or modify its claim that Extra Strength Excedrin will begin to relieve a headache in 15 minutes after the National Advertising Review Board upholds a previous National Advertising Division decision that the firm appealed, NARB says Nov. 24. The appeals division of the Council of Better Business Bureaus reviewed claim-substantiation materials that Novartis submitted to NAD after the firm's express claim for its headache product was challenged by Wyeth, which markets competing headache relief product Advil and has since been acquired by Pfizer (1"The Tan Sheet" March 23, 2009 and 2"The Tan Sheet" Oct. 26, 2009). In March, NAD decided that Novartis' substantiation did not support the claim that the product is the "only gel tab with a triple ingredient formula to start relieving your headache in just 15 minutes." NAD also considered an implied claim the product would provide considerable, if not total, relief in that time. NARB explained that it agrees with NAD's decision that "Novartis did not provide sufficient substantiation for the express claim that Extra Strength Excedrin starts to relieve headache pain in 15 minutes, and recommended that Novartis either discontinue or substantially modify that claim." According to NARB's report, Novartis said it "will, if it uses a similar claim in the future, take NAD's and NARB's conclusions into consideration in formulating and presenting the claim.

Related Content

Topics

UsernamePublicRestriction

Register

PS102737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel